Valiant Organics Ltd

Valiant Organics, a microcap in the Pharmaceuticals & Drugs sector, has reached a new 52-week low, continuing a downward trend with a notable decline over the past year. The stock's performance is below key moving averages, reflecting broader market influences and ongoing challenges within the sector.

Valiant Organics, a microcap in the Pharmaceuticals & Drugs sector, has hit a 52-week low, reflecting a 38.51% decline over the past year. The stock underperformed its sector and is trading below key moving averages, indicating ongoing volatility and challenges in its performance.

Valiant Organics, a microcap in the Pharmaceuticals and Drugs sector, has reached a 52-week low, trading just above this point. The stock has underperformed its sector and declined over the past year, contrasting with the positive performance of the Sensex, indicating ongoing challenges for the company.

Valiant Organics has recently undergone a revision in its score, reflecting ongoing challenges in the Pharmaceuticals & Drugs sector. Despite hitting a new 52-week low, the stock has shown signs of recovery after a prolonged decline. It has been added to MarketsMOJO's list, indicating a potential shift in market sentiment.

Valiant Organics has recently undergone a revision in its score, reflecting ongoing challenges in the Pharmaceuticals & Drugs sector. The stock has reached a new 52-week low and has consistently underperformed key moving averages, prompting its addition to MarketsMOJO's list. Investors are closely monitoring its performance amid a significant annual decline.

Valiant Organics, a smallcap pharmaceutical company, has been on a downward trend for the past 6 days, hitting a 52-week low on November 18, 2024. It has underperformed the sector by -0.69% and has been given a 'Strong Sell' rating by MarketsMOJO. The stock is currently trading below its moving averages and has had a negative 1-year performance compared to the Sensex.

Valiant Organics, a microcap pharmaceutical company, reported a negative performance in the quarter ending September 2024 with a score of -23, an improvement from -29 in the previous quarter. The company has maintained a low debt-equity ratio, but net sales and profits have seen significant declines. MarketsMOJO has given a 'Strong Sell' call for the company's stock.

Valiant Organics, a smallcap pharmaceutical company, has hit a 52-week low on November 14, 2024. The stock has been on a downward trend for the past 5 days, with a consecutive fall of -14.1%. According to MarketsMOJO, the stock has been given a 'Strong Sell' call due to its bearish trend and underperformance compared to the Sensex. Investors are advised to do their own research before investing.

Valiant Organics, a smallcap pharmaceutical company, has reported a decline in its financial performance for the quarter ended June 2024. The company's PBT and PAT have seen significant drops, while interest costs and net sales have also been negatively impacted. With low cash reserves and a slowdown in debt collection, investors should carefully evaluate before investing.

On April 1st, 2024, Valiant Organics, a smallcap pharmaceutical company, saw a 7.19% increase in its stock price, outperforming the sector by 6.08%. Despite three consecutive days of falling prices, the stock opened with a gain of 2.71% and reached an intraday high of Rs 407.1. According to MarketsMOJO, the stock is currently recommended as 'Strong Sell' based on its recent performance and market trends. While the company's stock is currently trading higher than its 5-day moving average, it remains lower than its 20-day, 50-day, 100-day, and 200-day moving averages. Over the past month, Valiant Organics has shown a decline of 4.20%, while the overall market has seen a slight increase of 0.58%. Despite this, the company continues to make strides in the pharmaceutical industry as a strong player in the market.

Valiant Organics, a smallcap pharmaceutical company, has been underperforming the sector with a -2.98% difference in performance today. The stock has hit a 52-week low and has seen a decline of -8.44% in the last three days. Despite a 3.47% increase today, the stock is currently trading below its moving averages, indicating a downward trend. MarketsMOJO has given a 'Strong Sell' call for the stock.

Valiant Organics, a smallcap pharmaceutical company, has seen a dip in its stock price, hitting a 52-week low of Rs. 390.05 on March 27, 2024. MarketsMOJO has given a 'Strong Sell' call due to the stock's downward trend and bearish sentiment. It has also underperformed compared to the Sensex in the past year. Investors should carefully evaluate before investing.

Valiant Organics, a smallcap pharmaceutical company, has seen a decline in its stock performance, with a -7.11% loss on March 13, 2024. The stock has been on a consecutive fall for the last four days, reaching an intraday high of Rs 429.75 and a low of Rs 391. The company's stock is currently trading below its moving averages, reflecting a downward trend. The pharmaceutical sector as a whole has also seen a decline of -2.33%.

Valiant Organics, a smallcap pharmaceutical company, saw a 7.04% increase in its stock price on March 5th, 2024, outperforming the sector by 7.14%. This marks the third consecutive day of gains, with a total increase of 7.94%. The company's strong fundamentals and positive trend in stock price make it a potential investment option.

Valiant Organics, a smallcap pharmaceutical company, reported a slight growth of 0.62% in net sales for the quarter ended September 2023, but a significant decline of -25.63% compared to the same quarter last year. The company's operating profit and net profit also saw a decline, but it has shown positive aspects such as generating the highest operating cash flow in three years and reducing its debt-equity ratio. However, there are concerns about declining sales and profits, increased interest expenses, and deteriorating liquidity. The company needs to improve its financial performance in the future.